|
Editorial
A
suit-able argument
The
recent controversy over market research firm IMS’ claim on
its data being superior to that of ORG-MARG and the government’s
own admission in the drug policy to the effect that ORG data is
not comprehensive and adequate has brought in an interesting and
challenging twist to the whole issue of drug price control.
Edit
Article
Biogenerics:
Novel opportunities
Biogenerics, the low cost alternative to biological products, presents
huge opportunities for Indian generic manufacturers in the post-GATT
era, say A N Nagappa, P A Thakurdesai and P L Kole
|
